5
ADT in monotherapy is not recommended in the guidelines for patients
with M1 disease1,2
SDo not offer ADT monotherapy to patients whose
first presentation is M1 disease if they have no
contra-indications for combination therapy and have a
sufficient life expectancy to benefit from combination
therapy (> 1 year) and are willing to accept the
increased risk of side effects.1
In men with mHSPC, ADT alone should be used
only in vulnerable men who cannot tolerate
treatment intensification2
IIIC
ADT, androgen deprivation therapy; M1, metastatic; mHSPC, metastatic hormone sensitive prostate cancer
1. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6. 2. ESMO Guidelines 2023. Fizazi K, Gillessem S. Ann Oncol.2023 Mar 14;S0923-7534(23)00111-4. 3. Gillessen S
et al. European Journal of Cancer 185 (2023) 178-215
What is your general treatment recommendation for the majority of
patients with mHSPC?3
Option 2
3%
Option 1
97%
1. Combination therapy (ADT
plus additional systemic
therapy and/or loca
radiotherapy)
2. ADT alone
3. Abstain/unqualified to
answer
